<https://rdf.molmedb.upol.cz/reference/ref3423> <http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method33>;
	<http://purl.org/ontology/bibo/pmid> "25589927"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM490584>,
		<https://identifiers.org/molmedb/MM490583>;
	<http://purl.org/ontology/bibo/doi> "10.1021/ml500353p"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM490585>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/membrane21>;
	<http://purl.org/dc/terms/bibliographicCitation> "Barsanti PA, Aversa RJ, Jin X, Pan Y, Lu Y, Elling R, Jain R, Knapp M, Lan J, Lin X, Rudewicz P, Sim J, Taricani L, Thomas G, Xiao L, Yue Q.: Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors. ACS Med Chem Lett, Volume 6 (1), 2015"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://rdf.molmedb.upol.cz/interaction/int1024188> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3423> .
<https://rdf.molmedb.upol.cz/interaction/int1024189> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3423> .
<https://rdf.molmedb.upol.cz/interaction/int1024191> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3423> .
<https://rdf.molmedb.upol.cz/interaction/int1024192> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3423> .
<https://rdf.molmedb.upol.cz/interaction/int1024193> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3423> .
<https://rdf.molmedb.upol.cz/interaction/int1024190> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3423> .